文献速递睡眠呼吸障碍

索利氨酚治疗OSA日间过度嗜睡的随机对照试验:依从与非依从亚组分析

Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
PubMed 文献 · Chest · 2021-02-22

结果显示索利氨酚改善嗜睡不依赖OSA治疗依从性,且未影响主要OSA治疗使用。

要点

  • 索利氨酚改善OSA相关日间过度嗜睡,无论患者是否依从主要OSA治疗。
  • 索利氨酚未对主要OSA治疗使用时长或使用比例产生临床有意义的影响。
  • 常见不良事件包括头痛、恶心、焦虑、食欲下降、鼻咽炎和腹泻。

核心结论

  • 索利氨酚改善OSA相关日间过度嗜睡,且不受主要OSA治疗依从性影响。
  • 索利氨酚未影响主要OSA治疗的使用。

研究设计与样本

  • 随机对照试验,参与者随机接受12周安慰剂或索利氨酚37.5、75、150、300 mg/d,按主要OSA治疗依从性分层。
  • 主要终点为改良意向治疗人群第12周40分钟维持觉醒试验(MWT)和Epworth嗜睡量表(ESS)较基线的变化。

主要发现

  • 依从组MWT睡眠潜伏期较安慰剂的最小二乘均值差异:37.5 mg/d为4.8分钟(95%CI 0.6-9.0),75 mg/d为8.4分钟(95%CI 4.3-12.5),150 mg/d为10.2分钟(95%CI 6.8-13.6),300 mg/d为12.5分钟(95%CI 9.0-15.9)。
  • 非依从组MWT睡眠潜伏期较安慰剂的最小二乘均值差异:37.5 mg/d为3.7分钟(95%CI -2.0至9.4),75 mg/d为9.9分钟(95%CI 4.4-15.4),150 mg/d为11.9分钟(95%CI 7.5-16.3),300 mg/d为13.5分钟(95%CI 8.8-18.3)。
  • 依从组ESS较安慰剂的最小二乘均值差异:37.5 mg/d为-2.4(95%CI -4.2至-0.5),75 mg/d为-1.3(95%CI -3.1至0.5),150 mg/d为-4.2(95%CI -5.7至-2.7),300 mg/d为-4.7(95%CI -6.1至-3.2)。
  • 非依从组ESS较安慰剂的最小二乘均值差异:37.5 mg/d为-0.7(95%CI -3.5至2.1),75 mg/d为-2.6(95%CI -5.4至0.1),150 mg/d为-5.0(95%CI -7.2至-2.9),300 mg/d为-4.6(95%CI -7.0至-2.3)。
  • 常见不良事件包括头痛、恶心、焦虑、食欲下降、鼻咽炎和腹泻。

关键数值与推荐

  • 主要OSA治疗依从定义为:每晚使用气道正压通气≥4小时且≥70%的夜晚,或手术干预,或使用口腔矫治器≥70%的夜晚。
  • 索利氨酚在美国获批用于改善OSA相关日间过度嗜睡,剂量范围为37.5-150 mg/d。

临床怎么用

  • 对于OSA相关日间过度嗜睡患者,可考虑使用索利氨酚改善嗜睡,无论其是否依从主要OSA治疗。
  • 使用索利氨酚时需监测常见不良事件如头痛、恶心、焦虑、食欲下降、鼻咽炎和腹泻。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Solriamfetol, a dopamine-norepinephrine reuptake inhibitor, is approved in the United States to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with OSA (37.5-150 mg/d). RESEARCH QUESTION: Does solriamfetol have differential effects on EDS based on adherence to primary OSA therapy and does solriamfetol affect primary OSA therapy use? STUDY DESIGN AND METHODS: Participants were randomized to 12 weeks of placebo or solriamfetol 37.5, 75, 150, or 300 mg/d (stratified by primary OSA therapy adherence). Coprimary end points were week 12 change from baseline in 40-min Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) in the modified intention-to-treat population. Primary OSA therapy use (hours per night, % nights) and safety were evaluated. RESULTS: At baseline, 324 participants (70.6%) adhered to OSA therapy (positive airway pressure use ≥ 4 h/night on ≥ 70% nights, surgical intervention, or oral appliance use on ≥ 70% nights) and 135 participants (29.4%) did not adhere. Least squares (LS) mean differences from placebo in MWT sleep latency (minutes) in the 37.5-, 75-, 150-, and 300-mg/d groups among adherent participants were 4.8 (95% CI, 0.6-9.0), 8.4 (95% CI, 4.3-12.5), 10.2 (95% CI, 6.8-13.6), and 12.5 (95% CI, 9.0-15.9) and among nonadherent participants were 3.7 (95% CI, -2.0 to 9.4), 9.9 (95% CI, 4.4-15.4), 11.9 (95% CI, 7.5-16.3), and 13.5 (95% CI, 8.8-18.3). On ESS, LS mean differences from placebo in the 37.5-, 75-, 150-, and 300-mg/d groups among adherent participants were -2.4 (95% CI, -4.2 to -0.5), -1.3 (95% CI, -3.1 to 0.5), -4.2 (95% CI, -5.7 to -2.7), and -4.7 (95% CI, -6.1 to -3.2) and among nonadherent participants were -0.7 (95% CI, -3.5 to 2.1), -2.6 (95% CI, -5.4 to 0.1), -5.0 (95% CI, -7.2 to -2.9), and -4.6 (95% CI, -7.0 to -2.3). Common adverse events included headache, nausea, anxiety, decreased appetite, nasopharyngitis, and diarrhea. No clinically meaningful changes were seen in primary OSA therapy use with solriamfetol. INTERPRETATION: Solriamfetol improved EDS in OSA regardless of primary OSA therapy adherence. Primary OSA therapy use was unaffected with solriamfetol. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02348606; URL: www.clinicaltrials.gov; EU Clinical Trials Register; No.: EudraCT2014-005514-31; URL: www.clinicaltrialsregister.eu.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Schweitzer PK, Mayer G, Rosenberg R, et al. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment. Chest. 2021. PMID: 33631141. doi:10.1016/j.chest.2021.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。